An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Limited research exists on aspirin-free strategies for complex percutaneous coronary intervention (PCI).
• Evaluating the efficacy and safety of an aspirin-free approach in this patient group is crucial.

Purpose of the Study:

• To assess the effectiveness and safety of an aspirin-free strategy versus standard dual antiplatelet therapy (DAPT) in patients undergoing complex PCI.
• To determine if aspirin cessation impacts major bleeding or cardiovascular events in this specific population.

Main Methods:

• A subgroup analysis from the STOPDAPT-3 trial was conducted, focusing on patients with complex PCI.
• Complex PCI was defined by criteria including multiple vessels, stents, lesions, long stent length, or chronic total occlusion.
• Patients received either low-dose prasugrel monotherapy (aspirin-free) or DAPT with low-dose prasugrel and aspirin.

Main Results:

• In complex PCI patients, the aspirin-free strategy showed no significant difference in major bleeding (5.30% vs 3.70%) compared to DAPT.
• Cardiovascular events were also not significantly different between the aspirin-free and DAPT groups in complex PCI patients (5.78% vs 5.93%).
• No significant interactions were observed for bleeding or cardiovascular outcomes between complex and non-complex PCI groups.

Conclusions:

• The aspirin-free strategy is comparable to standard DAPT regarding cardiovascular events and major bleeding in patients undergoing complex PCI.
• These findings suggest that an aspirin-free approach can be considered for patients with complex PCI.
• The study did not find a significant difference in outcomes regardless of PCI complexity.